TRPV2 channel as a possible drug target for the treatment of heart failure
- 1 February 2020
- journal article
- review article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 100 (2), 207-217
- https://doi.org/10.1038/s41374-019-0349-z
Abstract
No abstract availableFunding Information
- MEXT | Japan Society for the Promotion of Science (17k0598)
This publication has 94 references indexed in Scilit:
- The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responsesFrontiers in Immunology, 2013
- High cardiovascular morbidity and mortality in myofibrillar myopathies due to DES gene mutations: a 10-year longitudinal studyNeuromuscular Disorders, 2012
- The Role of TRP Proteins in Mast CellsFrontiers in Immunology, 2012
- CaMKII in myocardial hypertrophy and heart failureJournal of Molecular and Cellular Cardiology, 2011
- Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy studyJournal of Neuroinflammation, 2011
- Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic CardiomyopathyJournal of the American College of Cardiology, 2010
- Role of Inotropic Agents in the Treatment of Heart FailureCirculation, 2010
- TRPV2 has a pivotal role in macrophage particle binding and phagocytosisNature Immunology, 2010
- Probenecid, a gout remedy, inhibits pannexin 1 channelsAmerican Journal of Physiology-Cell Physiology, 2008
- Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruptionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007